Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Methacholine challenge test reveals a high prevalence of subclinical severe airway hyper-reactivity in children and young adults with sickle cell disease which correlates with higher sickle acute events and acute chest
source: American Society of Hematology
year: 2017
authors: Marthe-Sandrine Eiymo Mwa Mpollo, Sharat Chandra, Michael R. DeBaun, Uwe Christians, William Hardie, Karen Kalinyak, Punam Malik
summary/abstract:A total of 67 patients with SCD and 14 unaffected siblings of the patients enrolled on to the study for determining baseline AHR (ClinicalTrials.gov Identifier: NCT00448370). Chief eligibility criteria included a diagnosis of SCD (HbSS, HbSC or HbS b-thalassemia) confirmed by hemoglobin electrophoresis or gene sequencing, ages 5.5 years to 30 years who were able to complete pulmonary function testing and were at baseline/steady state (no acute sickle events 3 weeks prior or acute chest syndrome (ACS) 4 weeks prior). Excluded were patients taking anti-leukotriene medications within 30 days prior, although patients with SCD who had a known history of asthma but not on leukotriene inhibitors were eligible. Patients with chronic transfusions, congenital lung or heart condition, or other medical condition that could affect the pulmonary function testing were also ineligible. Unaffected siblings of the 67 enrolled SCD patients living in the same household were offered enrollment for MCT and those consenting were enrolled.
Results: 64 SCD patients and 14 siblings underwent a MCT; 3 of 67 SCD patients had FEV1<70% of predicted at baseline, and therefore, for safety reasons, were not subjected to MCT. The degree of AHR was defined by the provocative concentration of methacholine that resulted in a 20% decline in FEV1 (PC20): no AHR=PC20 >16mg/mL; borderline AHR=PC20 4-16mg/mL; mild AHR=PC20 1-3mg/mL and moderate-severe AHR=PC20 <1mg/mL. All subjects were given a dose of albuterol after completion of MCT. MCT was safe in all subjects, and no AHR or acute sickle events occurred in any subject for three weeks after the MCT. Overall, 25 of 67 (37%) SCD patients had no AHR, 8 of 67 (12%) had borderline AHR (PC20 9±1.4mg/ml), 10 of 67 (15%) had mild AHR (PC20 1.72 ±0.16) and 24 of 67 (36%) had moderate-severe AHR (PC20 0.6 ±0.06). Of unaffected siblings, 10 of 14 (71%) had no AHR, 2 of 14 (14%) had borderline AHR (PC20 10±0.4) and 2 of 14 (14%) had mild AHR (PC20 1.7±0.4). Moderate to severe AHR was only seen in SCD patients and not sibling controls. Severe AHR prevalence was highest in the HbSS group. We analyzed the clinical characteristics of the SCD subjects, including acute sickle episodes, defined as admission for one of the following: pain crises, fever with or without a known source of infection, cough/wheezing/chest pain, impending acute chest syndrome, enlarged and splenic sequestration or priapism. SCD patients with AHR had significantly higher (P<0.05) admissions from acute sickle episodes (2.7±0.1) and acute chest syndrome (1.5±0.15). We next assessed PlGF and leukotriene levels in SCD subjects. PlGF levels were not quantifiable due to presence of hemolysis, which confounds PlGF ELISA. However, we found a trend towards higher (1.3-2 fold) expression of PlGF-induced target genes (VEGF, IL-1β, IL-8, CCL2) in the mononuclear cells of patients with severe AHR; Also, circulating cysteinyl leukotriene D4 levels in their plasma were significantly higher.
organization: Cincinnati Children's Medical center, Cincinnati, OH; Vanderbilt University Medical Center, Nashville, TN; University of Colorado, Aurora, COread more
+myBinderRelated Content
-
Hydroxyurea Treatment in Men with SCA Leads to Drop in Total Sperm Count, Study ShowsResearchers found that treatment with hy...
-
Virtual Reality Helps Reduce Pain Among Patients With Sickle Cell DiseaseImmersive virtual reality appeared effec...
-
Acute Vaso-Occlusive Pain is Temporally Associated With the Onset of Menstruation in Women With Sickle Cell DiseaseBackground: Acute vaso-occlusive pain e...
-
Childhood hearing loss in patients with sickle cell disease in the United StatesThis study sought to examine if modern m...
-
Cognitive Function may be Affected in Adults With Sickle Cell Disease, Study SuggestsAdults with sickle cell disease score wo...
-
Sickle cell gene linked to elevated risk of developing kidney failureNew research indicates that being born w...
-
Study Confirms Safe Use of Opioids for Pain Control in Sickle Cell DiseaseThe most common cause of hospital admiss...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.